Business
Gelesis New Clinical Data on Impact of Gelesis100
Gelesis New Clinical Data on Impact of Gelesis100.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 9329T PureTech Health PLC 25 March 2019 \n\n25 March 2019\n \nPureTech Health plc\n \nPureTech's Affiliate Gelesis Presents Data Supporting Lead Product Candidate's Positive Effect on People with Prediabetes, Untreated Diabetes, and Elevated Insulin Resistance\n \nIndividuals with prediabetes and those with untreated type 2 diabetes had six times higher odds to achieve ≥10% weight loss compared to placebo\n \nIndividuals with high insulin resistance achieved significant drop in HOMA-IR levels on treatment independent of their level of weight loss\n \nPureTech Health plc (LSE: PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis, is pleased to note that its affiliate Gelesis today presented clinical data at ENDO 2019, the Endocrine Society's annual meeting, suggesting that elevated fasting plasma glucose could be a useful and unique predictor to identify individuals who have higher adjusted odds to achieve significant weight loss with the Company's lead product candidate, Gelesis100.\n \nFurthermore, individuals with high insulin resistance, as measured by HOMA-IR, at the start of the trial had a statistically significant reduction in HOMA-IR over the six-month treatment period - an effect observed both among those who lost significant weight while taking Gelesis100 and those who did not. Elevated insulin resistance is a significant driver of diabetes.\n \nGelesis100 is a superabsorbent hydrogel in development for the potential treatment of overweight and obesity. Data shared at ENDO 2019 show that individuals with prediabetes and untreated type 2 diabetes were particularly responsive to Gelesis100 in the pivotal GLOW study. They had six times higher odds of achieving ≥10% weight loss over six months, compared to placebo. Across the entire treatment group in the GLOW study, baseline fasting plasma glucose was correlated with greater weight loss (R =-0.24, P = 0.0144). The pronounced weight loss effect of Gelesis100 treatment in this population, which is at higher clinical risk, was also observed in a previous pilot study. \n \nEric Elenko, PhD, chief innovation officer at PureTech Health, said: \"These findings suggest that Gelesis100 could be an important new tool for aiding...